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Abstract
Introduction Neutrophil extracellular traps (NETs) are
formed by activated neutrophils during the process of
NETosis in which the nuclear material is released into
extracellular space, including DNA molecules, citrullinated
histones, and neutrophil granule enzymes, such as elastase.
This material forms networks that are able not only to
physically entrap bacteria but also to provide elevated
concentration of bactericidal components. Over the last
years, it has become clear that NETs can also be formed
under numerous sterile inflammatory conditions, i.e.,
thrombosis, cancer, SLE, atherosclerosis, and diabetes.
Method We reviewed studies published until July 2016 to
find possible associations between elevated cell-free DNA
levels in dialyzed patients and the process of NETosis and
its consequences.
Results The process of NETosis, its elevated activation, or
impaired clearance provides the link between clinical
conditions and elevated levels of cell-free DNA found in
plasma after the hemodialytic procedure which itself is able
to activate neutrophils via platelets and ROS formation.
NETs stimulate thrombosis and endothelial damage, and
their formation may contribute to the development of
spectrum of comorbidities described in dialyzed patients.
Conclusion The study of plasma cell-free DNA levels
together with markers of NETosis could contribute to the
evaluation of the influence of hemodialysis on the immune
system of patients.
Keywords Neutrophil extracellular trap  NETosis 
Cell-free DNA  Hemodialysis  Diabetes  Thrombosis 
Atherosclerosis
Introduction
The fact that neutrophils can form extracellular traps
(neutrophil extracellular traps—NETs) containing DNA to
kill bacteria was first observed and described in 2004 by
Brinkmann and colleagues [1]. The term ‘‘NETosis’’ has
been coined in 2007 by Steinberg and Grinstein [2] to
denote the neutrophil cell death in consequence of this
newly described mechanism of innate immune response
primarily recognized as defense against microbial
infection.
Since the discoveries, the process of NETosis has
been explored in greater detail. It has been found that it
can be activated not only by bacterial infection but also
under sterile conditions associated with thrombosis,
cancer, atherosclerosis, and diabetes [3]. The first results
documenting the role of NETosis in hemodialysed (HD)
patients were published [4, 5] as well as articles eluci-
dating the functional connections between NETosis and
comorbidities frequently found in HD patients, such as
diabetes, chronic inflammation, major adverse cardio-
vascular events, autoimmune diseases, and cancer
[4, 6–13].
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We studied the cell-free DNA (cfDNA) levels in plasma
in HD patients before and after a hemodialysis session [14].
In accordance with others similar studies [15, 16], we
found elevated cfDNA concentrations in plasma after the
procedure. In patients undergoing the peritoneal dialysis,
the relationship between the cfDNA concentration in dia-
lysate and the overall length of therapy has been found
[14]. The recent knowledge with regard to the process of
NETosis elucidates these previously obtained results.
In present minireview, our attempt is to summarize what
is recently known about the NETosis generally and about
the connection between this process; hemodialysis and
comorbidities in HD patients with the goal to stimulate
intensive research of this interesting phenomenon with
multiple potential clinical applications not exclusively for
HD patients.
General characteristics of NETosis
Morphological and molecular features of NETosis
NETosis is described as a new type of a programmed cell
death following the multi-step highly coordinated scenario
based on histone citrullination, chromatin decondensation,
migration of elastase and other neutrophil granule enzymes
into the nucleus, disintegration of nuclear membranes, and
the release of neutrophil extracellular traps (NETs) con-
taining DNA, citrullinated histones, and enzymes of
neutrophil granules into extracellular space. NETs are
characterized by specific ultrastructure. They are formed by
chromatin filaments having 15–17 nm in diameter [1]. The
filaments can be organized into cloud-like structures and
occupy a 10–15-fold larger area than the cell from which
they originated [17]. The NETs contain not only DNA and
histones (histones account for 70% of their protein con-
tent), but also globular structures of about 50 nm in
diameter are observed inside the NETs. Such structures
represent the source of numerous components of neutrophil
granules, such as neutrophil elastase (NE), myeloperoxi-
dase (MPO), cathepsin G, proteinase 3, BPI (cationic
bactericidal/permeability increasing protein), calgranulin,
a-defensins, lactoferrin, and a fragment of the protein
cathelicidin hCAP18—the peptide LL-37, and pentraxin
PTX3, matrix-metalloproteinase 9 (MMP-9), and peptido-
glycan recognition protein-S (PGRP-S) [17–20].
Different types of cell death are usually defined by
morphological criteria (Table 1) [21]. Recently, it has
become clear that all these modes of cell death are inter-
connected at the molecular level by the network of
overlapping signaling pathways; therefore, it has been
proposed to use instead the terms ‘‘apoptosis’’, ‘‘au-
tophagy’’, and ‘‘necrosis’’; the term ‘‘regulated
necroptosis’’ for all cases of cell death is not caused acci-
dentally by external factors [22]. As the extracellular traps
containing chromatin may be extruded also by eosinophils,
mast cells, and monocytes/macrophages, the term ETosis
(concerning Extracellular Traps formation) has been pro-
posed to denote this process [17].
The methods allowing the quantification of NETosis-
specific markers are elaborated and the first reports con-
cerning their use appeared [23, 24]. Unfortunately, some
methods are based on artificial stimulation of NETosis in
isolated cell population in vitro (e.g., stimulation of cells
with phorbol myristate [23]) and they are not applicable to
analysis of plasma samples. ELISA with anti-MPO anti-
bodies seems to be most promising methods for analysis of
cell-free samples followed by flow cytometry with fluo-
rescent dye SYTOX Green which label DNA but do not
enter intact cells [24].
Activation of NETosis
The molecular mechanisms activating the process of
NETosis are not fully understood. It is clear that the ROS
play one of the most important roles in this event. The best
inducer of NEtosis in vitro is phorbol 12-myristate 13-ac-
etate (PMA) which belongs to strong inducers of ROS
generation [25]. ROS are probably needed for oxidative
modifications of macromolecules including DNA. Activa-
tion of neutrophils involves the activity of NADPH oxidase
complex on the cytoplasmic membrane and on the mem-
brane of neutrophil granules. Neutrophils without the
ability to form NETs are found in patients with chronic
granulomatous disease (CGD) caused by mutation in a
gene for NAPH oxidase subunit [26]. Signal transduction
from the receptors to NADPH oxidase is dependent on Raf/
MEK/ERK-signaling pathway [27] and also on Rac-2-
mediated pathway [28].
Molecular events associated with NETosis
During the first hour after activation of NETosis, the
nucleus loses its lobules, the membranes of nuclear
envelope separate, and later, they form vesicles, chromatin
decondenses, and the neutrophil granules disintegrate.
Then, nucleoplasm and cytoplasm merge, cytoplasmic
membrane is broken, and the content of the cell is released
into extracellular space to form the NET [17]. Enzymes of
primary (azurophilic) granules of neutrophils—neutrophil
elastase (NE) and myeloperoxidase (MPO)—participate in
the process of chromatin decondensation. After the initia-
tion of NETosis, they are transported in granules into the
nucleus, where NE cleaves the linker histone H1 and
modifies core histones. Mice deficient in this enzyme are
not able to produce NETs [29]. The process of NET
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formation is also impaired in patients with mutations in the
MPO gene [30]. The enzyme peptidylarginine deiminase 4
(PAD 4) catalyzes deamination of arginine residues
yielding citrullines in the core histones. Citrullination of
histones is found in decondensed chromatin [31–33]. The
PAD4 activity and the presence of citrullinated histones are
regarded as very useful specific markers of NETosis [34],
because PAD4 is suppressed after induction of apoptosis
[32].
The modification of the process of NETosis which does
not lead to the cell death has also been described. This
process is referred as vital NETosis in contrast to the
above-mentioned process of suicidal NETosis [35]. Vital
NETosis may be induced in different ROS-independent
ways, and NETs are then excreted from vesicles formed
within cytoplasm and fusing with cell membrane. Neu-
trophils after vital NETosis despite the complete loss of the
nucleus retain their biological functions, such as chemo-
taxis and phagocytosis [36–38]. Among the stimuli leading
to activation of vital NETosis, the microbial ligands, toll-
like receptors (TLR 2 and 4), and platelets were recognized
as the most important players [36–38].
ROS-dependent formation of NETs from mitochondrial
DNA but not nuclear DNA by viable neutrophils has also
been observed [39]. Neutrophil extracellular traps formed
after major trauma and subsequent surgery contain mtDNA
[40].
Antimicrobial activity of NETs was explored widely.
The fact that NETs avoid the dissemination of bacteria in
the body has been proven in experiments employing
artificial bacterial infection of animals and their treatment
with DNases [37]. The study of microbicidal properties of
NETs has not provided clear results. Microbicidal activity
of histones was reported [3], but DNA is thought to be the
major antimicrobial component of NETs [41]. On the
contrary, it has been reported that the bacteria captured in
NETs and subsequently released using DNase preserved
full viability [42]. Blood plasma contains large amount of
protease inhibitors which may effectively inactivate the
NET components, and the experiments demonstrating the
microbicidal activity of NETs were performed in a serum-
free medium [35]. Therefore, further studies are needed for
elucidation of all NET functions.
NETs with their complex composition may be consid-
ered as typical representatives of alarmins. Alarmins were
defined as molecules providing a danger signal associated
not only with infections but also with tissue damage.
According to the definition [43], alarmins can be released
passively from dying cells or actively from stimulated
immune cells, and they can diffuse and induce the immune
response, including the sterile inflammation and tissue
reparation. DNA belongs to the strong activators of
immune system. Different immune cells are equipped by
endosomal and cytosolic receptors for recognition of
autologous DNA molecules. Plasmacytoid dendritic cells
contain, e.g., the endosomal receptor TLR9, and mono-
cytes/macrophages have numerous other cytosolic
receptors. The recognition of DNA by these receptors
activates the signal pathways leading to synthesis of
interferons of type I (I IFN) and a number of pro-
Table 1 Classification of distinct types of cell death according to the recommendations of the Nomenclature Committee on Cell Death 2009 [21]
and to recent knowledge of interconnected signaling pathways [22]
Cell death type Main characteristics
Regulated necroptosis
[22]
Apoptosis Rounding-up of the cell
Nuclear fragmentation
DNA fragmentation
Plasma membrane blebbing and rupture
Activation of caspases
Apoptotic bodies formation
Minor modification of cytoplasmic organelles
ROS overgeneration
Engulfment by resident phagocytes in vivo
Autophagy Lack of chromatin condensation
Digestion of cellular organelles—accumulation of
autophagic vacuoles
Massive vacuolization of the cytoplasm
Necrosis Regulated necrosis = necroptosis (including
NETosis)
Cytoplasmic swelling (oncosis)
Rupture of plasma membrane and spilling of intracellular
content
ROS overgeneration
Accidental necrosis Caused by external factors
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inflammatory cytokines. Complexes containing DNA
associated with the peptide LL-37 which also belongs to
the NET components are endocytosed by TLR9 bearing
endosomes, and the regulatory pathways stimulates the I
IFN synthesis (reviewed in detail in [17]). In opposite way,
the inflammatory cytokines may trigger the process of
NETosis similarly to microbial liposacharides, immune
complexes, and autoantibodies [6].
NET clearance
The clearance of NETs is not fully understood. In vitro, the
NETs are degraded by the addition of DNase 1 [1]. The
role of DNase 1 in NET degradation has also been proven
in vivo [44, 45]. It is known that circulating DNA has a
short half-life (10–15 min) [16, 46]. Impaired process of
NET clearance is considered as an important pre-requisite
in the development of autoimmune diseases, namely, sys-
temic lupus erythematosus (SLE) has been explored with
regard to involvement of NETs in its pathogenesis—the
antibodies against all components of NETs were found in
the blood of SLE patients [17].
NETosis and dialysis
NETosis and hemodialysis
The levels of cell-free DNA (cfDNA) were studied before
the start and after the completion of a hemodialysis pro-
cedure. Irrespective of the type of hemodialysis membrane,
the mutually confirming results were obtained by inde-
pendent studies [14–16]. All studies reported the elevation
of concentrations of cfDNA in patients’ plasma after the
procedure, but it has been difficult to interpret such results.
Atamaniuk et al. [15] correlated the levels of cfDNA in HD
patients with levels of markers of apoptosis in their plasma
and concluded that there is an increased level of apoptosis
in blood of patients during hemodialysis. On the contrary,
we were not able to correlate the elevated levels of cfDNA
with decreased numbers of leucocytes in patient’s blood
after the procedure [47]. Simultaneously, the fact that the
hemodialysis activates neutrophils, and consequently, the
elevated production of microparticles from neutrophils and
platelets as non-specific markers of neutrophil activation
during dialysis-induced inflammation has been reported
[48].
Tovbin et al. [49] regarded cfDNA as an integrative
marker of tissue damage. Their study evaluated postdial-
ysis cfDNA levels as an independent predictor of all-cause
mortality in HD patients.
Jeong da Wun et al. [5] studied the levels of cfDNA in
HD patients with diabetes and with cardiovascular
diseases. They reported increased levels of cfDNA in these
patients in comparison with HD patients without such
comorbidities. The levels of cfDNA correlated positively
with the counts of white blood cells. The researchers
concluded that uncontrolled hypertension and poor gly-
cemic control are independent determinants for the
elevated cfDNA. As McGuire et al. [50] demonstrated that
cfDNA levels are not influenced by renal impairment but
do reflect endothelial dysfunction in patients with chronic
kidney disease (CKD), and the study by Jeong da Wun
et al. [5] stated that cfDNA might be a marker of vascular
injury rather than pro-inflammatory condition in HD
patients.
In the opposite way, cfDNA in plasma of HD patients
may stimulate the production of IL-6 as demonstrated in an
experimental study by Atamaniuk et al. [51]. The
researchers studied the effects of plasma collected from
HD patients on the activity of monocytes in vitro. Plasma
from HD patients but not from healthy controls or DNase
I-treated HD plasma induced IL-6 production from
monocytes. The study concluded that the cfDNA contained
in plasma of HD patients selectively stimulates the pro-
duction of the pro-inflammatory cytokine interleukin IL-6
in human monocytes. Jeong et al. [4] in 2016 as the first
researchers connected all the known facts and took the
process of NETosis in account when studying HD patients
and their risk of major adverse cardiovascular events
(MACE).
The researchers measured NET formation markers,
including DNA-histone complexes and cfDNA, neutrophil
elastase, and IL-6 in HD patients and investigated their
potential as predictors of cardiovascular risk and mortality.
They also focused on the exploration of the role of uremic
toxins with regard to their potential to stimulate the pro-
duction of DNA-histone complexes and cfDNA in
peripheral neutrophils from normal volunteers. This study
provided the evidence that uremic toxins induce DNA-hi-
stone complex formation and the elevated levels of cfDNA
in an in vitro experiment. The levels of DNA-histone
complexes were evaluated as a significant independent
predictor of major adverse cardiovascular events (MACE)
in HD patients.
The DNA-histone complexes were regarded as markers
of NET formation associated with inflammatory conditions
in this study. Inflammatory status of studied HD patients
was confirmed by elevated levels of inflammatory cytokine
IL-6.
NETosis and peritoneal dialysis
In our study [14], we detected cfDNA in overnight efflu-
ents of patients undergoing peritoneal dialysis (PD). The
concentrations of cfDNA in these effluents correlated
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inversely with the duration of PD treatment. The activation
of the process of NETosis through the effects of glucose
degradation products (GDP) in peritoneal dialysis solutions
gives the clue to the explanation of this phenomenon.
Chronic exposure of the peritoneal membrane to GDPs and
dextrose leads to the formation of advanced glycosylation
end products (AGEs) that bind to receptors for AGE
(RAGE). It leads to the generation of several cytokines
stimulating inflammatory changes in the peritoneal space
[52]. The elevated level of glucose itself is able to con-
tribute to the enhanced activation of NETosis as has been
demonstrated experimentally with neutrophils from dia-
betic humans and mice which were primed to produce
NETs [8]. AGEs may mediate the activation of NADPH
oxidase and predispose neutrophils to NETosis [53]. Ban-
sal et al. [54] investigated the effect of AGE on reactive
oxygen and nitrogen species generation and subsequent
oxidative stress in neutrophils. This study provided evi-
dence that AGEs may play a key role in the induction of
oxidative stress in neutrophils which is the pre-requisite for
activation of NETosis. Neutrophils from non-diabetic
individuals are prone to NETosis when exposed to high
glucose [9]. Osmotic stress also induces the process of
NETosis [55].
NETosis in peritoneal cavity in the response to the
treatment by peritoneal dialysis has not been studied yet. It
seems that the research focused on this problem could
provide new interesting insights into the complex regula-
tory network associated with biocompatibility of PD
solutions.
NETosis and frequent comorbidities
in hemodialyzed patients
The elevated levels of NET formation or their persistence
have been demonstrated in clinical disorders which fre-
quently occur in HD patients—cardiovascular diseases,
including atherosclerosis and thrombosis [10], diabetes II
[8], autoimmune diseases, such as systemic lupus erythe-
matosus [11], and wide spectrum of oncologic diseases
[13].
Cardiovascular diseases
Cardiovascular disease belongs to the major causes of
morbidity and mortality in HD patients with end-stage
renal disease [56]. It has been shown that the presence of
cfDNA together with platelet–neutrophil interactions
may promote microvascular thrombosis [6]. Increased
levels of cfDNA were reported in patients with deep
vein thrombosis, and NET formation was detected as
essential for development of venous thrombosis [12, 57].
Multiple mechanisms are discussed as being potentially
involved in the pathogenic activation of coagulation in
the presence of NETs. These mechanisms are based on
extracellular release of tissue factors, activity of
polyanionic surface of NETs, or proteolytic cleavage of
tissue factors and serpins by elastase released by neu-
trophils during NETosis [6].
The complex role of NETosis in pathogenesis of
atherosclerosis has been partially elucidated. Cholesterol
crystals activate the release of NETs, which are able to
stimulate macrophages to release the cytokines. In this
manner, the immune cell recruitment into atherotic plaques
is intensified [58]. NETosis activated by lipopolysacharides
of bacterial walls also explains the old theory postulating
that the presence of periodontal pathogens in blood may
start the atherosclerotic changes [59]. Endothelial dys-
function is regarded as crucial in pathogenesis of
atherosclerosis. Activated endothelial cells are able to
stimulate NETosis, but on the other hand, they are them-
selves damaged by NETs [60]. In severe
glomerulonephritis, NET-related extracellular histones
promote vascular necrosis [61].
Diabetes
Exacerbated NETosis is known as factor complicating
wound healing in diabetic patients [8]. The high glucose
levels contribute to the activation of NETosis [8, 9].
NETosis can play role in the onset of type I diabetes, where
the components of NETs activate autoimmune processes
[62].
Autoimmune diseases
NETs were detected in affected kidneys in patients with
SLE [63], in autoimmune small-vessel vasculitis [64], and
in vasculitis lesions associated with anti-neutrophil cyto-
plasmic antibodies (ANCA) [65]. The presence of NETs in
impaired tissues provides the evidence that neutrophils are
included in pathogenesis, but it is not clear whether they
initiate the glomerular or vascular tissue damage or whe-
ther they only contribute to acceleration of an
independently activated process [34]. In patients with SLE,
the imbalance between NET formation and NET clearance
was reported. Increased number of dying lymphocytes in
the blood of SLE patients correlates with increased titers of
anti-DNA autoantibodies. Simultaneously, SLE sera have
reduced capacity to degrade NETs [34].
In rheumatoid arthritis, the autoantibodies to a citrulli-
nated protein fillagrin are detected. Many patients also
express the autoantibodies to histones. Therefore, it is
reasonable to suppose that the NETosis is also involved in
the pathogenesis of this disease [34].
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Oncologic diseases
The study of the roles of NETosis in cancerogenesis repre-
sents an exciting newly emerging topic with many practical
implications. It has been reviewed in detail by Cools-Lar-
tigue et al. [13]. Neutrophils were recognized as important
components of the tumor-associated inflammatory cell
infiltrates [66, 67]. Their roles in tumor biology are inten-
sively studied, and both pro- and anti-tumorigenic properties
are found [68]. The role of cytokines as tumor necrosis factor
alpha (TNF-a) and interleukin 8 (IL-8) in the facilitation of
the process of NET formation was proven. Both these
cytokines are released by numerous primary tumor types
[13]. The results of the first performed studies suggest a
possible association between intra-tumoral NET deposition
and tumor progression [66, 67]. The ability of tumor cells to
predispose circulating neutrophils to produce NETs was
demonstrated in different tumor types [69]. In the context of
carcinogenesis, it is hypothesized that NETs may play a
similar role as in limitation of bacterial infection—they
provide high local concentrations of biologically active
proteins which are able to promote proliferation and inhibit
apoptosis. With regard to metastasis, the NETs can entrap
circulating tumor cells. The NET component—matrix-met-
alloproteinase 9 (MMP-9)—participates in the degradation
of the extracellular matrix, and it is involved in tissue
remodeling, angiogenesis, and tumor progression [70].
Neutrophil elastase contained in NETs may also participate
in extracellular matrix degradation (especially in the cleav-
age of elastin) and tissue remodeling to facilitate the tumor
growth [71]. Another component of NETs—cathepsin G—
facilitates angiogenesis and tumor cell dissemination [72].
NETs are recognized by leukocytes including macrophages
and dendritic cells [13], and in this manner, the persistent
inflammatory state may be established. This way, NET
deposition could create a ‘‘pre-metastatic niche’’. It is known
that systemic sepsis promotes the development of metastasis
and administration of inhibitors of NET formation was able
to attenuate this process [13]. The study by Cools-Lartigue
et al. [66] demonstrated that disruption of NETs using either
DNase or neutrophil elastase inhibitors avoids cell adhesion
and metastasis formation. This study highlighted NETs as
possible therapeutic targets. Treatment with DNase seems to
be clinically safe as reported in patients with SLE [73].
Future perspectives of NETosis exploration
in dialyzed patients
The interconnections among processes of NETosis activa-
tion and clearance, clinical conditions, and known
laboratory and clinical outcomes are schematically pre-
sented in Fig. 1.
It seems that cfDNA if regarded in association with
other markers of NETosis may become from an analyte of
unknown meaning to an important marker providing not
only the information about the reaction of patient’s
immune response to hemodialysis. In the group of HD
patients studied by us previously, we found rarely the
individuals in which plasma cfDNA levels decreased due
the process of hemodialysis [14, 47]. It is also necessary to
study the inter-individual differences in the NETosis per-
formance with regard to clinical status of HD patients to be
able to understand and clarify such observations.
The response to the hemodialytic procedure quantified
as elevation of NETosis should be taken into account in the
treatment of patients according to the severity of their
comorbidities especially diabetes, cardiovascular, and
autoimmune diseases.
Further studies focused on the elucidation of mecha-
nisms of NET clearance, and the possible therapeutic
interventions allowing the regulation of this process are
needed. It is necessary to keep in mind that NETosis
functions as a double-edged sword—the balance between
correct immune system performance and the potential
damaging effects of exacerbated NETosis should be
achieved in HD patients with different comorbidities.
The first attempts in this direction have been made. The
physiological consequences of NETosis blocking began to
be studied [66, 74]. The first study dealing with the levels
of cfDNA as markers of NETosis in HD patients appeared
[4], but the complicated relationships among the process of
hemodialysis, performance of NETosis, and clinical out-
comes of HD patients remain to be elucidated in the future.
PubMed search focused on the term ‘‘NETosis’’ revealed
234 references but only 13 articles for combination of key
words ‘‘NETosis’’ and ‘‘Nephrology’’ in July 2016. It is
necessary to follow periodically the development in this
interdisciplinary field, because it may bring not only novel
insights into the pathogenesis of comorbidities in dialyzed
patients, but also clinically useful new diagnostic tests.
Conclusion
• Elevated plasma levels of cell-free DNA after a
hemodialysis procedure may be activated by NETosis
which occurs as a consequence of activation of neu-
trophils during the process of hemodialysis.
• NETs play crucial roles in pathogenesis of numerous
comorbidities of HD patients, such as diabetes, cardio-
vascular and autoimmune diseases.
• Better understanding of NETs formation, clearance,
and inter-individual differences in this processes is
needed for the development of proper diagnostic and
therapeutic approaches.
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• The study of plasma cell-free DNA levels together with
markers of NETosis could also contribute to evaluation
of the influence of hemodialysis on patient’s immune
system and to the prediction and management of
clinical outcomes with regard to patient’s
comorbidities.
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